10-Q Filing

SWK Holdings Corp CIK: 1089907 Q2 2021

Filing Information

Form Type	10-Q
Accession Number	`0001552781-21-000666`
Period End Date	20210630
Filing Date	20210816
Fiscal Year	2021
Fiscal Period	Q2
XBRL Instance	e21515_swkh-10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 82 Cash Flow Statement 74 Stockholders Equity 31

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, Par or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, Par or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.62M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$17.17M	USD	Point-in-time
Preferred Stock, Shares Issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, Shares Issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$11.16M	USD	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$2.64M	USD	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$1.91M	USD	Point-in-time
Preferred Stock, Shares Outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, Shares Outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Marketable investments	`MarketableSecurities`	$1.21M	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Marketable investments	`MarketableSecurities`	$2.42M	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.15M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$542.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$6.67M	USD	Point-in-time
Common Stock, Shares, Issued	`CommonStockSharesIssued`	12.80M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$12.83M	USD	Point-in-time
Common Stock, Shares, Issued	`CommonStockSharesIssued`	12.79M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	12.80M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	12.79M	shares	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$204.49M	USD	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$202.97M	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$241.00K	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$210.00K	USD	Point-in-time
Cost method investment	`CostMethodInvestments`	$3.49M	USD	Point-in-time
Cost method investment	`CostMethodInvestments`	$3.49M	USD	Point-in-time
Deferred tax asset, net	`DeferredIncomeTaxAssetsNet`	$27.49M	USD	Point-in-time
Deferred tax asset, net	`DeferredIncomeTaxAssetsNet`	$23.12M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$2.97M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$3.86M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$11.13M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$13.62M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$5.72M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$5.21M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.31M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.09M	USD	Point-in-time
Total assets	`Assets`	$273.90M	USD	Point-in-time
Total assets	`Assets`	$272.82M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.08M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.65M	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	$11.76M	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$15.41M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.08M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$10.67M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$16.90M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$843.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$1.08M	USD	Point-in-time
Total liabilities	`Liabilities`	$33.39M	USD	Point-in-time
Total liabilities	`Liabilities`	$14.59M	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,798,547 and 12,792,586 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$13.00K	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,798,547 and 12,792,586 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$13.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.17B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.19B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$240.51M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$236.53M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$232.00M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$244.08M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$232.08M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$258.24M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$273.90M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$272.82M	USD	Point-in-time

Income Statement 82 line items

Line Item	Tag	Value	Unit	Period
Finance receivables interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$11.80M	USD	1 Quarter
Finance receivables interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$20.48M	USD	2 Qtrs
Finance receivables interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$7.73M	USD	1 Quarter
Finance receivables interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$14.87M	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$10.66M	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$298.00K	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$150.00K	USD	1 Quarter
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$10.46M	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	-	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$20.00K	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$496.00K	USD	2 Qtrs
Other	`RevenueNotFromContractWithCustomerOther`	$38.00K	USD	2 Qtrs
Total revenues	`Revenues`	$31.64M	USD	2 Qtrs
Total revenues	`Revenues`	$22.27M	USD	1 Quarter
Total revenues	`Revenues`	$7.90M	USD	1 Quarter
Total revenues	`Revenues`	$15.21M	USD	2 Qtrs
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	2 Qtrs
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	$163.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$163.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$264.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$239.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$94.00K	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$1.54M	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$2.16M	USD	2 Qtrs
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$1.01M	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$3.09M	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	1 Quarter
Depreciation and amortization expense	`DepreciationAndAmortization`	$2.49M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$3.44M	USD	1 Quarter
Depreciation and amortization expense	`DepreciationAndAmortization`	$811.00K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationAndAmortization`	$6.95M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$6.25M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$3.36M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.69M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.65M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$5.66M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$11.92M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$9.05M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$17.01M	USD	2 Qtrs
Unrealized net gain (loss) on warrants	`UnrealizedGainLossOnDerivatives`	$892.00K	USD	2 Qtrs
Unrealized net gain (loss) on warrants	`UnrealizedGainLossOnDerivatives`	$609.00K	USD	1 Quarter
Unrealized net gain (loss) on warrants	`UnrealizedGainLossOnDerivatives`	$622.00K	USD	1 Quarter
Unrealized net gain (loss) on warrants	`UnrealizedGainLossOnDerivatives`	$-1.24M	USD	2 Qtrs
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-488.00K	USD	2 Qtrs
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$1.22M	USD	2 Qtrs
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$402.00K	USD	1 Quarter
Unrealized net gain (loss) on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$283.00K	USD	1 Quarter
Income (loss) before income tax expense (benefit)	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$17.50M	USD	1 Quarter
Income (loss) before income tax expense (benefit)	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-125.00K	USD	1 Quarter
Income (loss) before income tax expense (benefit)	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$21.83M	USD	2 Qtrs
Income (loss) before income tax expense (benefit)	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-3.53M	USD	2 Qtrs
Income tax expense (benefit)	`IncomeTaxExpenseBenefit`	$252.00K	USD	2 Qtrs
Income tax expense (benefit)	`IncomeTaxExpenseBenefit`	$4.47M	USD	2 Qtrs
Income tax expense (benefit)	`IncomeTaxExpenseBenefit`	$-1.00M	USD	1 Quarter
Income tax expense (benefit)	`IncomeTaxExpenseBenefit`	$3.53M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Consolidated net income (loss)	`ProfitLoss`	$-4.66M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$17.36M	USD	2 Qtrs
Consolidated net income (loss)	`ProfitLoss`	$13.97M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$3.39M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$876.00K	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.09	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.29	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$1.36	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.07	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.29	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$1.09	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$1.35	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$0.07	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.80M	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.90M	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.91M	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.79M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.91M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.83M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.91M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.82M	shares	2 Qtrs

Cash Flow Statement 74 line items

Line Item	Tag	Value	Unit	Period
Consolidated net income (loss)	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Consolidated net income (loss)	`ProfitLoss`	$-4.66M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$17.36M	USD	2 Qtrs
Consolidated net income (loss)	`ProfitLoss`	$13.97M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$3.39M	USD	1 Quarter
Consolidated net income (loss)	`ProfitLoss`	$876.00K	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	2 Qtrs
Impairment expense	`OperatingLeaseImpairmentLoss`	-	USD	1 Quarter
Impairment expense	`OperatingLeaseImpairmentLoss`	$163.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$93.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$94.00K	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$252.00K	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$4.37M	USD	2 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$1.24M	USD	2 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$-892.00K	USD	2 Qtrs
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-488.00K	USD	2 Qtrs
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$1.22M	USD	2 Qtrs
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$402.00K	USD	1 Quarter
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$283.00K	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$1.79M	USD	1 Quarter
Loan discount amortization and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$965.00K	USD	2 Qtrs
Loan discount amortization and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$1.13M	USD	2 Qtrs
Interest paid-in-kind	`PaidInKindInterest`	$1.75M	USD	2 Qtrs
Interest paid-in-kind	`PaidInKindInterest`	$26.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$364.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$177.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$183.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$370.00K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$2.49M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$6.95M	USD	2 Qtrs
Interest and accounts receivable	`IncreaseDecreaseInInterestAndDividendsReceivable`	$553.00K	USD	2 Qtrs
Interest and accounts receivable	`IncreaseDecreaseInInterestAndDividendsReceivable`	$-728.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$1.16M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$477.00K	USD	2 Qtrs
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$889.00K	USD	2 Qtrs
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-813.00K	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$19.25M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.13M	USD	2 Qtrs
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$20.10M	USD	2 Qtrs
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$6.11M	USD	2 Qtrs
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$22.78M	USD	2 Qtrs
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$3.26M	USD	2 Qtrs
Corporate debt securities principal payment	`MarketableInvestmentPrincipalPayment`	$33.00K	USD	2 Qtrs
Corporate debt securities principal payment	`MarketableInvestmentPrincipalPayment`	$31.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$671.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.49M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$172.00K	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-163.00K	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.47M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.20M	USD	2 Qtrs
Net (payments on) proceeds from credit facility	`ProceedsFromRepaymentsOfLinesOfCredit`	$-11.76M	USD	2 Qtrs
Net (payments on) proceeds from credit facility	`ProceedsFromRepaymentsOfLinesOfCredit`	$6.45M	USD	2 Qtrs
Payment of acquisition-related contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	-	USD	2 Qtrs
Payment of acquisition-related contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	$6.08M	USD	2 Qtrs
Repurchases of common stock, including fees and expenses	`PaymentsForRepurchaseOfCommonStock`	-	USD	2 Qtrs
Repurchases of common stock, including fees and expenses	`PaymentsForRepurchaseOfCommonStock`	$1.09M	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.35M	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-17.84M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$3.61M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$6.01M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$3.01M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.62M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$17.17M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$11.16M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.01M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.62M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$17.17M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$11.16M	USD	Point-in-time

Stockholders Equity 31 line items

Line Item	Tag	Value	Unit	Period
Balances at December 31, 2019	`StockholdersEquity`	$240.51M	USD	Point-in-time
Balances at December 31, 2019	`StockholdersEquity`	$236.53M	USD	Point-in-time
Balances at December 31, 2019	`StockholdersEquity`	$232.00M	USD	Point-in-time
Balances at December 31, 2019	`StockholdersEquity`	$244.08M	USD	Point-in-time
Balances at December 31, 2019	`StockholdersEquity`	$232.08M	USD	Point-in-time
Balances at December 31, 2019	`StockholdersEquity`	$258.24M	USD	Point-in-time
Stock-based compensation	`ShareBasedCompensation`	$364.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$177.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$183.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$370.00K	USD	2 Qtrs
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Net income	`ProfitLoss`	$-3.78M	USD	2 Qtrs
Net income	`ProfitLoss`	$-4.66M	USD	1 Quarter
Net income	`ProfitLoss`	$17.36M	USD	2 Qtrs
Net income	`ProfitLoss`	$13.97M	USD	1 Quarter
Net income	`ProfitLoss`	$3.39M	USD	1 Quarter
Net income	`ProfitLoss`	$876.00K	USD	1 Quarter
Balances at June 30, 2020	`StockholdersEquity`	$240.51M	USD	Point-in-time
Balances at June 30, 2020	`StockholdersEquity`	$236.53M	USD	Point-in-time
Balances at June 30, 2020	`StockholdersEquity`	$232.00M	USD	Point-in-time
Balances at June 30, 2020	`StockholdersEquity`	$244.08M	USD	Point-in-time
Balances at June 30, 2020	`StockholdersEquity`	$232.08M	USD	Point-in-time
Balances at June 30, 2020	`StockholdersEquity`	$258.24M	USD	Point-in-time
Repurchases of common stock in open market	`StockRepurchasedDuringPeriodValue`	$62.00K	USD	1 Quarter
Repurchases of common stock in open market	`StockRepurchasedDuringPeriodValue`	$1.03M	USD	1 Quarter
Issuance of common stock in lieu of payment of employee cash bonuses	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$60.00K	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.